Bionomics Limited (NASDAQ:BNOX) to Post FY2023 Earnings of ($3.26) Per Share, Cantor Fitzgerald Forecasts

Bionomics Limited (NASDAQ:BNOXGet Rating) – Equities research analysts at Cantor Fitzgerald dropped their FY2023 EPS estimates for Bionomics in a report issued on Thursday, September 15th. Cantor Fitzgerald analyst C. Duncan now expects that the company will earn ($3.26) per share for the year, down from their prior forecast of ($2.94). The consensus estimate for Bionomics’ current full-year earnings is ($2.49) per share.

Bionomics Stock Down 2.6 %

NASDAQ BNOX opened at $7.19 on Monday. The company has a fifty day simple moving average of $7.46 and a two-hundred day simple moving average of $7.81. Bionomics has a 12-month low of $5.70 and a 12-month high of $22.00.

Institutional Trading of Bionomics

A hedge fund recently bought a new stake in Bionomics stock. Woodline Partners LP bought a new stake in Bionomics Limited (NASDAQ:BNOXGet Rating) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 161,943 shares of the company’s stock, valued at approximately $2,032,000. Woodline Partners LP owned 2.89% of Bionomics as of its most recent SEC filing. Hedge funds and other institutional investors own 6.79% of the company’s stock.

Bionomics Company Profile

(Get Rating)

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.

Read More

Receive News & Ratings for Bionomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionomics and related companies with's FREE daily email newsletter.